Alzex Neuropharma
TRRI · OTC
Price unavailable right now.
No price history for this range.
Key indicators
TRRI profitability and balance sheet ratios
Debt to assets 1.2% in Sep 2013.
| Period | Debt to assets |
|---|---|
| Mar 2013 | 1.9% |
| Jun 2013 | 2.1% |
| Sep 2013 | 1.2% |
Income statement
No financial statements are reported for Alzex Neuropharma.
Balance sheet
What the company owns and owes at period end
Total assets
Total liabilities
| Line item | Mar 2013 | Jun 2013 | Sep 2013 |
|---|---|---|---|
| Total assets | $0.0M | $0.0M | $0.1M |
| Total liabilities | $0.2M | $0.2M | $0.3M |
| Shareholder equity | −$0.2M | −$0.2M | −$0.2M |
| Cash and short-term investments | $0.0M | $0.0M | −$0.0M |
| Total debt | $0.1M | $0.1M | $0.1M |
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.